The best indicator for Bristol Myers Squibb (BMY)
We backtested 366 indicators across daily, weekly and hourly charts on real Bristol Myers Squibb (BMY) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
QQE
On the weekly chart, this is the strongest risk-adjusted edge we found for Bristol Myers Squibb (BMY) over ~54.2 years — beating buy-and-hold by 0.8% CAGR.
Best multi-indicator combo
Going long only when all 2 agree was the strongest confluence setup we found for Bristol Myers Squibb (BMY) — trailing buy-and-hold by 4.0% CAGR, out-of-sample. Fewer, higher-conviction trades than any single indicator.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | QQE ✓ | Weekly | 11.0% | 0.55 | -56.3% | 47.9% | 163 | 0.8% |
| 2 | Volume Flow Indicator ✓ | Weekly | 9.6% | 0.55 | -51.3% | 46.7% | 15 | -0.6% |
| 3 | DEMA 200 Trend ✓ | Weekly | 8.1% | 0.55 | -42.5% | 48.9% | 47 | -2.1% |
| 4 | SMC: Change of Character ✓ | Weekly | 9.4% | 0.54 | -51.6% | 57.1% | 21 | -0.9% |
| 5 | Ichimoku Cloud ✓ | Weekly | 8.3% | 0.53 | -56.1% | 39.7% | 58 | -2.0% |
| 6 | Positive Volume Index ✓ | Weekly | 7.8% | 0.53 | -53.8% | 38.1% | 21 | -2.4% |
| 7 | EMA 10/40 Cross ✓ | Weekly | 8.8% | 0.53 | -57.6% | 41.9% | 31 | -1.5% |
| 8 | WMA 100 Trend ✓ | Weekly | 8.2% | 0.52 | -67.5% | 39.2% | 51 | -2.0% |
| 9 | TRIX (21) ✓ | Weekly | 8.5% | 0.52 | -59.1% | 52.9% | 17 | -1.8% |
| 10 | G-Channel ✓ | Weekly | 8.4% | 0.52 | -59.0% | 44.1% | 59 | -1.8% |
| 11 | EMA 50/200 Cross ✓ | Daily | 8.6% | 0.51 | -62.0% | 36.7% | 30 | -1.8% |
| 12 | McGinley 200 Trend ✓ | Daily | 10.3% | 0.51 | -70.6% | 21.1% | 19 | -0.1% |
| 13 | EMA 20/50 Cross ✓ | Weekly | 8.2% | 0.51 | -62.5% | 47.6% | 21 | -2.1% |
| 14 | WMA 20/80 Cross ✓ | Weekly | 8.4% | 0.51 | -59.0% | 40.9% | 22 | -1.9% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Bristol Myers Squibb (BMY), QQE on the weekly timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.